FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308196675> ?p ?o ?g. }

• W4308196675 endingPage "1330" @default.
• W4308196675 startingPage "1321" @default.
• W4308196675 abstract "To evaluate the eosinophil changes, efficacy and safety of pembrolizumab treatment in advanced urothelial carcinoma patients of older age and those with a poor performance status (PS).Consecutive patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy between January 2018 and June 2021 were retrospectively examined.105 patients (median age, 72 years), 71.4% of whom were men, were enrolled. Patients of ≥75 years of age were considered to be older patients (n=40), and patients with PS ≥2 were considered to have a poor PS (n=10). The objective response and disease control rates were 42.5% and 52.5%, respectively, in older patients and 0% and 10.0%, respectively, in patients with a poor PS. Overall survival (OS) in the older and younger groups did not differ to a statistically significant extent. However, a poor PS was significantly associated with poor survival. Safety analyses demonstrated no significant difference in the occurrence of any immune-related adverse events (irAEs), including grade ≥3, between the older and younger groups. However, a poor PS was significantly associated with the low occurrence of any irAEs. The change of the eosinophil count, the increase of the relative eosinophil count (REC) and the decrease of the neutrophil-to-eosinophil ratio (NER) did not differ to a statistically significant extent between the older and younger groups, but showed significant differences between the poor and good PS (PS 0-1) groups.Pembrolizumab for advanced UC demonstrated similar changes in the eosinophil count, efficacy and toxicity in both older and younger patients. In patients with a poor PS, although toxicity was significantly lower, survival was significantly worse, and neither an increase in REC nor a decrease in NER were observed, but these values showed significant changes in patients with a good PS." @default.
• W4308196675 created "2022-11-09" @default.
• W4308196675 creator A5005824874 @default.
• W4308196675 creator A5008310613 @default.
• W4308196675 creator A5011256581 @default.
• W4308196675 creator A5012284662 @default.
• W4308196675 creator A5012292098 @default.
• W4308196675 creator A5017068775 @default.
• W4308196675 creator A5020076297 @default.
• W4308196675 creator A5039626009 @default.
• W4308196675 creator A5045893818 @default.
• W4308196675 creator A5047054113 @default.
• W4308196675 creator A5052095996 @default.
• W4308196675 creator A5057956395 @default.
• W4308196675 creator A5071222216 @default.
• W4308196675 creator A5073793517 @default.
• W4308196675 creator A5082566636 @default.
• W4308196675 date "2022-11-01" @default.
• W4308196675 modified "2023-10-18" @default.
• W4308196675 title "The Eosinophil Changes, Efficacy and Safety of Pembrolizumab in Advanced Urothelial Carcinoma Patients with an Older Age and a Poor Performance Status" @default.
• W4308196675 cites W1867318780 @default.
• W4308196675 cites W2019607817 @default.
• W4308196675 cites W2093679650 @default.
• W4308196675 cites W2103257412 @default.
• W4308196675 cites W2120562400 @default.
• W4308196675 cites W2288908606 @default.
• W4308196675 cites W2342631834 @default.
• W4308196675 cites W2397854274 @default.
• W4308196675 cites W2588916311 @default.
• W4308196675 cites W2767373080 @default.
• W4308196675 cites W2776730914 @default.
• W4308196675 cites W2789677706 @default.
• W4308196675 cites W2794976313 @default.
• W4308196675 cites W2897038355 @default.
• W4308196675 cites W2945430578 @default.
• W4308196675 cites W2950551738 @default.
• W4308196675 cites W2955884544 @default.
• W4308196675 cites W2964650688 @default.
• W4308196675 cites W2989792268 @default.
• W4308196675 cites W2999769024 @default.
• W4308196675 cites W3010223451 @default.
• W4308196675 cites W3021590305 @default.
• W4308196675 cites W3043479599 @default.
• W4308196675 cites W3087464965 @default.
• W4308196675 cites W3087788702 @default.
• W4308196675 cites W3165458897 @default.
• W4308196675 cites W3208585924 @default.
• W4308196675 cites W4225393626 @default.
• W4308196675 cites W2990571891 @default.
• W4308196675 doi "https://doi.org/10.2147/ott.s389138" @default.
• W4308196675 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36388155" @default.
• W4308196675 hasPublicationYear "2022" @default.
• W4308196675 type Work @default.
• W4308196675 citedByCount "0" @default.
• W4308196675 crossrefType "journal-article" @default.
• W4308196675 hasAuthorship W4308196675A5005824874 @default.
• W4308196675 hasAuthorship W4308196675A5008310613 @default.
• W4308196675 hasAuthorship W4308196675A5011256581 @default.
• W4308196675 hasAuthorship W4308196675A5012284662 @default.
• W4308196675 hasAuthorship W4308196675A5012292098 @default.
• W4308196675 hasAuthorship W4308196675A5017068775 @default.
• W4308196675 hasAuthorship W4308196675A5020076297 @default.
• W4308196675 hasAuthorship W4308196675A5039626009 @default.
• W4308196675 hasAuthorship W4308196675A5045893818 @default.
• W4308196675 hasAuthorship W4308196675A5047054113 @default.
• W4308196675 hasAuthorship W4308196675A5052095996 @default.
• W4308196675 hasAuthorship W4308196675A5057956395 @default.
• W4308196675 hasAuthorship W4308196675A5071222216 @default.
• W4308196675 hasAuthorship W4308196675A5073793517 @default.
• W4308196675 hasAuthorship W4308196675A5082566636 @default.
• W4308196675 hasBestOaLocation W43081966751 @default.
• W4308196675 hasConcept C121608353 @default.
• W4308196675 hasConcept C126322002 @default.
• W4308196675 hasConcept C197934379 @default.
• W4308196675 hasConcept C2776042228 @default.
• W4308196675 hasConcept C2776694085 @default.
• W4308196675 hasConcept C2776907518 @default.
• W4308196675 hasConcept C2777037409 @default.
• W4308196675 hasConcept C2777701055 @default.
• W4308196675 hasConcept C2780057760 @default.
• W4308196675 hasConcept C2780352672 @default.
• W4308196675 hasConcept C2911057145 @default.
• W4308196675 hasConcept C3019882237 @default.
• W4308196675 hasConcept C71924100 @default.
• W4308196675 hasConcept C90924648 @default.
• W4308196675 hasConceptScore W4308196675C121608353 @default.
• W4308196675 hasConceptScore W4308196675C126322002 @default.
• W4308196675 hasConceptScore W4308196675C197934379 @default.
• W4308196675 hasConceptScore W4308196675C2776042228 @default.
• W4308196675 hasConceptScore W4308196675C2776694085 @default.
• W4308196675 hasConceptScore W4308196675C2776907518 @default.
• W4308196675 hasConceptScore W4308196675C2777037409 @default.
• W4308196675 hasConceptScore W4308196675C2777701055 @default.
• W4308196675 hasConceptScore W4308196675C2780057760 @default.
• W4308196675 hasConceptScore W4308196675C2780352672 @default.
• W4308196675 hasConceptScore W4308196675C2911057145 @default.
• W4308196675 hasConceptScore W4308196675C3019882237 @default.
• W4308196675 hasConceptScore W4308196675C71924100 @default.

• next